Cadrenal Therapeutics (NASDAQ:CVKD) CEO Quang Pham Sells 12,996 Shares

Cadrenal Therapeutics, Inc. (NASDAQ:CVKD) CEO Quang Pham sold 12,996 shares of Cadrenal Therapeutics stock in a transaction on Friday, June 12th. The stock was sold at an average price of $3.94, for a total transaction of $51,204.24. Following the completion of the transaction, the chief executive officer owned 136,381 shares in the company, valued at $537,341.14. This trade represents a 8.70% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link.

Cadrenal Therapeutics Trading Down 10.0%

CVKD traded down $0.37 during trading on Monday, hitting $3.33. The stock had a trading volume of 67,393 shares, compared to its average volume of 66,405. The firm has a market cap of $9.56 million, a PE ratio of -0.59 and a beta of 1.60. Cadrenal Therapeutics, Inc. has a 12 month low of $3.27 and a 12 month high of $14.64. The company has a 50 day simple moving average of $5.01 and a 200-day simple moving average of $6.59.

Cadrenal Therapeutics (NASDAQ:CVKD) last announced its earnings results on Thursday, May 7th. The company reported ($1.04) EPS for the quarter, topping the consensus estimate of ($1.51) by $0.47. As a group, sell-side analysts anticipate that Cadrenal Therapeutics, Inc. will post -5.52 earnings per share for the current fiscal year.

Institutional Trading of Cadrenal Therapeutics

Institutional investors have recently made changes to their positions in the business. Citadel Advisors LLC acquired a new stake in shares of Cadrenal Therapeutics during the 3rd quarter valued at about $274,000. DRW Securities LLC acquired a new stake in shares of Cadrenal Therapeutics during the 4th quarter valued at about $171,000. JPMorgan Chase & Co. acquired a new stake in shares of Cadrenal Therapeutics during the 3rd quarter valued at about $103,000. Finally, Geode Capital Management LLC boosted its position in shares of Cadrenal Therapeutics by 14.3% during the 4th quarter. Geode Capital Management LLC now owns 14,528 shares of the company’s stock valued at $98,000 after acquiring an additional 1,818 shares in the last quarter. 7.92% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

Several analysts have issued reports on the stock. Weiss Ratings restated a “sell (e+)” rating on shares of Cadrenal Therapeutics in a research report on Monday, April 20th. Wall Street Zen upgraded shares of Cadrenal Therapeutics from a “strong sell” rating to a “sell” rating in a research report on Saturday, May 9th. Finally, HC Wainwright decreased their price target on shares of Cadrenal Therapeutics from $32.00 to $13.00 and set a “buy” rating on the stock in a research report on Tuesday, April 7th. One analyst has rated the stock with a Buy rating and one has assigned a Sell rating to the stock. According to data from MarketBeat.com, the company presently has an average rating of “Hold” and an average price target of $13.00.

Cadrenal Therapeutics Company Profile

Cadrenal Therapeutics, Inc operates as a clinical development biopharmaceutical company. The company focuses on developing Tecarfarin, a novel oral and reversible anticoagulant to prevent heart attacks, strokes, and deaths due to blood clots in patients with rare cardiovascular conditions requiring chronic anticoagulation, such as patients with left ventricular assist devices, end-stage kidney disease, atrial fibrillation, and thrombotic anti-phospholipid syndrome. Cadrenal Therapeutics, Inc was incorporated in 2022 and is headquartered in Ponte Vedra, Florida.